SciClone Pharmaceuticals, Inc.
SCICLONE PHARMACEUTICALS INC (Form: 4, Received: 03/09/2017 17:25:38)
FORM 4
[ ] Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).         
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES
                                                                                  
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response...
0.5
                      
Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940
                      

1. Name and Address of Reporting Person *

Cheung Wilson Wai-Shun
2. Issuer Name and Ticker or Trading Symbol

SCICLONE PHARMACEUTICALS INC [ SCLN ]
5. Relationship of Reporting Person(s) to Issuer (Check all applicable)

_____ Director                      _____ 10% Owner
__ X __ Officer (give title below)      _____ Other (specify below)
CFO & Senior VP, Finance
(Last)          (First)          (Middle)

950 TOWER LANE, SUITE 900
3. Date of Earliest Transaction (MM/DD/YYYY)

3/8/2017
(Street)

FOSTER CITY, CA 94404
(City)        (State)        (Zip)
4. If Amendment, Date Original Filed (MM/DD/YYYY)

 
6. Individual or Joint/Group Filing (Check Applicable Line)

_ X _ Form filed by One Reporting Person
___ Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1.Title of Security
(Instr. 3)
2. Trans. Date 2A. Deemed Execution Date, if any 3. Trans. Code
(Instr. 8)
4. Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5)
5. Amount of Securities Beneficially Owned Following Reported Transaction(s)
(Instr. 3 and 4)
6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price

Table II - Derivative Securities Beneficially Owned ( e.g. , puts, calls, warrants, options, convertible securities)
1. Title of Derivate Security
(Instr. 3)
2. Conversion or Exercise Price of Derivative Security 3. Trans. Date 3A. Deemed Execution Date, if any 4. Trans. Code
(Instr. 8)
5. Number of Derivative Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5)
6. Date Exercisable and Expiration Date 7. Title and Amount of Securities Underlying Derivative Security
(Instr. 3 and 4)
8. Price of Derivative Security
(Instr. 5)
9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Restricted Stock Unit   (1)   (2) 3/8/2017     A      12000         (3) 3/8/2027   Common Stock   12000   $0   125500   D    
Incentive Stock Option (right to buy)   (1) $9.65   3/8/2017     A      10651         (4) 3/8/2027   Common Stock   10651   $0   10651   D    
Non-Qualified Stock Options (right to buy)   (1) $9.65   3/8/2017     A      73349         (4) 3/8/2027   Common Stock   73349   $0   73349   D    

Explanation of Responses:
( 1)  Granted under the Issuer's 2015 Equity Incentive Plan.
( 2)  Each restricted stock unit represents the right to receive, at settlement, one share of common stock.
( 3)  Vesting for such RSUs will occur 25% on March 8, 2018, 25% on March 8, 2019, 25% on March 8, 2020, and 25% on March 8, 2021, contingent upon the executive's continued employment.
( 4)  25% of such shares vest from one year from the date of grant and 2.0833% vests each month thereafter, provided that the Reporting Person continues to be employed by the Issuer.

Reporting Owners
Reporting Owner Name / Address
Relationships
Director 10% Owner Officer Other
Cheung Wilson Wai-Shun
950 TOWER LANE, SUITE 900
FOSTER CITY, CA 94404


CFO & Senior VP, Finance

Signatures
/s/ Wilson W. Cheung 3/9/2017
** Signature of Reporting Person Date


Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4(b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.